Last 12 months
Inside the activity.
7 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 2 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2021 Filed Mar 1, 2021 17:32 UTC |
Couturier ChristopheEVP, Services
|
GrantCommon Stock | 6,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000090 · wf-form4_161463791486976.xml · nonDerivative · entry 1 Couturier Christophe · CIK 0001684076 · EVP, Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,192 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 17:38 UTC |
Peacock Jonathan MDirector
|
GrantCommon Stock | 7,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000099 · wf-form4_161463828573565.xml · nonDerivative · entry 1 Peacock Jonathan M · CIK 0001500241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,431 F1 · kind: Reflects a grant of restricted stock units that vests on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:29 UTC |
Szlosek Thomas AEVP & CFO
|
GrantStock Options (Right to Buy) · Derivative | 52,693 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001722482-21-000085 · wf-form4_161463773392835.xml · derivative · entry 2 Szlosek Thomas A · CIK 0001293167 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,693 Underlying: Common Stock · 52,693 shares Expires 2031-02-25 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:29 UTC |
Szlosek Thomas AEVP & CFO
|
GrantCommon Stock | 16,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000085 · wf-form4_161463773392835.xml · nonDerivative · entry 1 Szlosek Thomas A · CIK 0001293167 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,655 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:31 UTC |
SACHDEV RAKESHDirector
|
GrantCommon Stock | 7,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000089 · wf-form4_161463789184347.xml · nonDerivative · entry 1 SACHDEV RAKESH · CIK 0001259543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,841 F1 · kind: Reflects a grant of restricted stock units that vests on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:34 UTC |
SEVERINO MICHAELDirector
|
GrantCommon Stock | 7,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000093 · wf-form4_161463806896980.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,258 F1 · kind: Reflects a grant of restricted stock units that vests on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:36 UTC |
Shaw ChristiDirector
|
GrantCommon Stock | 7,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000096 · wf-form4_161463815280490.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,555 F1 · kind: Reflects a grant of restricted stock units that vests on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 23:01 UTC |
Eck Steven WSVP & Chief Accounting Officer
|
GrantStock Options (Right to Buy) · Derivative | 19,906 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001722482-21-000100 · wf-form4_161463965294064.xml · derivative · entry 2 Eck Steven W · CIK 0001748813 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,906 Underlying: Common Stock · 19,906 shares Expires 2031-02-25 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 23:01 UTC |
Eck Steven WSVP & Chief Accounting Officer
|
GrantCommon Stock | 6,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000100 · wf-form4_161463965294064.xml · nonDerivative · entry 1 Eck Steven W · CIK 0001748813 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,084 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:38 UTC |
Andres JuanDirector
|
GrantCommon Stock | 7,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000098 · wf-form4_161463825991602.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,187 F1 · kind: Reflects a grant of restricted stock units that vests on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:33 UTC |
Stubblefield MichaelDirector · President and CEO
|
GrantStock Options (Right to Buy) · Derivative | 234,192 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001722482-21-000091 · wf-form4_161463795186396.xml · derivative · entry 2 Stubblefield Michael · CIK 0001776153 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,192 Underlying: Common Stock · 234,192 shares Expires 2031-02-25 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:33 UTC |
Stubblefield MichaelDirector · President and CEO
|
GrantCommon Stock | 72,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000091 · wf-form4_161463795186396.xml · nonDerivative · entry 1 Stubblefield Michael · CIK 0001776153 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,509,481 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:35 UTC |
Lewis SheriEVP, Global Ops & Supply Chain
|
GrantStock Options (Right to Buy) · Derivative | 43,911 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001722482-21-000094 · wf-form4_161463809781461.xml · derivative · entry 2 Lewis Sheri · CIK 0001839410 · EVP, Global Ops & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,911 Underlying: Common Stock · 43,911 shares Expires 2031-02-25 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:35 UTC |
Lewis SheriEVP, Global Ops & Supply Chain
|
GrantCommon Stock | 13,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000094 · wf-form4_161463809781461.xml · nonDerivative · entry 1 Lewis Sheri · CIK 0001839410 · EVP, Global Ops & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,856 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 25, 2022 Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:30 UTC |
Ohri DevashishEVP, IMEA
|
GrantStock Options (Right to Buy) · Derivative | 17,564 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001722482-21-000087 · wf-form4_161463782495888.xml · derivative · entry 2 Ohri Devashish · CIK 0001776125 · EVP, IMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,564 Underlying: Common Stock · 17,564 shares Expires 2031-02-25 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:30 UTC |
Ohri DevashishEVP, IMEA
|
GrantCommon Stock | 5,427 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000087 · wf-form4_161463782495888.xml · nonDerivative · entry 1 Ohri Devashish · CIK 0001776125 · EVP, IMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,888 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:30 UTC |
Henson MeghanEVP, Chief HR Officer
|
GrantCommon Stock · Derivative | 26,347 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001722482-21-000086 · wf-form4_161463778186478.xml · derivative · entry 2 Henson Meghan · CIK 0001839411 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,347 Underlying: Common Stock · 26,347 shares Expires 2031-02-25 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:30 UTC |
Henson MeghanEVP, Chief HR Officer
|
GrantCommon Stock | 8,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000086 · wf-form4_161463778186478.xml · nonDerivative · entry 1 Henson Meghan · CIK 0001839411 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,902 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:28 UTC |
Miller JustinEVP & General Counsel
|
GrantStock Options (Right to Buy) · Derivative | 26,347 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001722482-21-000084 · wf-form4_161463768080582.xml · derivative · entry 2 Miller Justin · CIK 0001776122 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,347 Underlying: Common Stock · 26,347 shares Expires 2031-02-25 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:28 UTC |
Miller JustinEVP & General Counsel
|
GrantCommon Stock | 8,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000084 · wf-form4_161463768080582.xml · nonDerivative · entry 1 Miller Justin · CIK 0001776122 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,574 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:27 UTC |
Wondrasch MichaelEVP & CIO
|
GrantStock Options (Right to Buy) · Derivative | 26,347 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001722482-21-000083 · wf-form4_161463762340106.xml · derivative · entry 2 Wondrasch Michael · CIK 0001776065 · EVP & CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,347 Underlying: Common Stock · 26,347 shares Expires 2031-02-25 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:27 UTC |
Wondrasch MichaelEVP & CIO
|
GrantCommon Stock | 8,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000083 · wf-form4_161463762340106.xml · nonDerivative · entry 1 Wondrasch Michael · CIK 0001776065 · EVP & CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,474 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:26 UTC |
Vanderhaegen FredericEVP, Europe
|
GrantStock Options (Right to Buy) · Derivative | 52,693 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001722482-21-000082 · wf-form4_161463756733714.xml · derivative · entry 2 Vanderhaegen Frederic · CIK 0001776162 · EVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,693 Underlying: Common Stock · 52,693 shares Expires 2031-02-25 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:26 UTC |
Vanderhaegen FredericEVP, Europe
|
GrantCommon Stock | 16,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000082 · wf-form4_161463756733714.xml · nonDerivative · entry 1 Vanderhaegen Frederic · CIK 0001776162 · EVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,669 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:25 UTC |
Brophy GerardEVP, Biopharma Production
|
GrantStock Options (Right to Buy) · Derivative | 52,693 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001722482-21-000080 · wf-form4_161463743593570.xml · derivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,693 Underlying: Common Stock · 52,693 shares Expires 2031-02-25 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:25 UTC |
Brophy GerardEVP, Biopharma Production
|
GrantCommon Stock | 16,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000080 · wf-form4_161463743593570.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,665 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:25 UTC |
Murray Mark ChristopherEVP, Biomaterials & AT
|
GrantStock Options (Right to Buy) · Derivative | 26,347 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001722482-21-000081 · wf-form4_161463752751676.xml · derivative · entry 2 Murray Mark Christopher · CIK 0001800013 · EVP, Biomaterials & AT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,347 Underlying: Common Stock · 26,347 shares Expires 2031-02-25 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:25 UTC |
Murray Mark ChristopherEVP, Biomaterials & AT
|
GrantCommon Stock | 8,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000081 · wf-form4_161463752751676.xml · nonDerivative · entry 1 Murray Mark Christopher · CIK 0001800013 · EVP, Biomaterials & AT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,598 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 25, 2022. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:44 UTC |
Eck Steven WSVP & Chief Accounting Officer
|
Tax withholdingCommon Stock | 2,577 | $27.94 | $72,001.38 |
DisclosureSEC source: 0001722482-21-000059 · wf-form4_161438302413386.xml · nonDerivative · entry 2 Eck Steven W · CIK 0001748813 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,955 F2 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of performance stock units. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:44 UTC |
Eck Steven WSVP & Chief Accounting Officer
|
Exercise / conversionCommon Stock | 8,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000059 · wf-form4_161438302413386.xml · nonDerivative · entry 1 Eck Steven W · CIK 0001748813 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares were received for no consideration upon the satisfaction of performance criteria underlying an award of performance stock units. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:34 UTC |
Brophy GerardEVP, Biopharma Production
|
SaleCommon Stock | 3,059 | $27.93 | $85,437.87 |
DisclosureSEC source: 0001722482-21-000057 · wf-form4_161438242739247.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,384 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 17:41 UTC |
Bramwell JamesEVP, Strategic Partners
|
Tax withholdingCommon Stock | 1,216 | $28.69 | $34,887.04 |
DisclosureSEC source: 0001722482-21-000047 · wf-form4_161412004564878.xml · nonDerivative · entry 1 Bramwell James · CIK 0001776099 · EVP, Strategic Partners 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,214 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 17:50 UTC |
Couturier ChristopheEVP, Services
|
Tax withholdingCommon Stock | 1,313 | $28.69 | $37,669.97 |
DisclosureSEC source: 0001722482-21-000053 · wf-form4_161412059067162.xml · nonDerivative · entry 1 Couturier Christophe · CIK 0001684076 · EVP, Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,408 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. F2 · balance_after: Includes 789 shares acquired under the Avantor Employee Stock Purchase Plan. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:38 UTC |
Szlosek Thomas AEVP & CFO
|
Tax withholdingCommon Stock | 2,980 | $28.69 | $85,496.20 |
DisclosureSEC source: 0001722482-21-000045 · wf-form4_161411990842127.xml · nonDerivative · entry 1 Szlosek Thomas A · CIK 0001293167 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,374 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. F2 · balance_after: Includes 1,355 shares acquired under the Avantor Employee Stock Purchase Plan. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:47 UTC |
Wondrasch MichaelEVP & CIO
|
Tax withholdingCommon Stock | 1,209 | $28.69 | $34,686.21 |
DisclosureSEC source: 0001722482-21-000052 · wf-form4_161412045008508.xml · nonDerivative · entry 1 Wondrasch Michael · CIK 0001776065 · EVP & CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,334 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:51 UTC |
Brophy GerardEVP, Biopharma Production
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 19,769 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001722482-21-000054 · wf-form4_161412066010117.xml · derivative · entry 4 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,306 Underlying: Common Stock · 19,769 shares Expires 2030-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Reflects an initial grant of 79,075 stock options that vest in four equal installments beginning on February 21, 2021. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:51 UTC |
Brophy GerardEVP, Biopharma Production
|
SaleCommon Stock | 19,769 | $28.62 | $565,788.78 |
DisclosureSEC source: 0001722482-21-000054 · wf-form4_161412066010117.xml · nonDerivative · entry 3 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,443 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.54 to $28.67, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:51 UTC |
Brophy GerardEVP, Biopharma Production
|
Exercise / conversionCommon Stock | 19,769 | $17.67 | $349,318.23 |
DisclosureSEC source: 0001722482-21-000054 · wf-form4_161412066010117.xml · nonDerivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:51 UTC |
Brophy GerardEVP, Biopharma Production
|
Tax withholdingCommon Stock | 3,072 | $28.69 | $88,135.68 |
DisclosureSEC source: 0001722482-21-000054 · wf-form4_161412066010117.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,443 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:46 UTC |
Miller JustinEVP & General Counsel
|
Tax withholdingCommon Stock | 1,350 | $28.69 | $38,731.50 |
DisclosureSEC source: 0001722482-21-000051 · wf-form4_161412033264961.xml · nonDerivative · entry 1 Miller Justin · CIK 0001776122 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,434 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. F2 · balance_after: Includes 1,277 shares acquired under the Avantor Employee Stock Purchase Plan. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:44 UTC |
Eck Steven WSVP & Chief Accounting Officer
|
Tax withholdingCommon Stock | 449 | $28.69 | $12,881.81 |
DisclosureSEC source: 0001722482-21-000050 · wf-form4_161412025968151.xml · nonDerivative · entry 1 Eck Steven W · CIK 0001748813 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,982 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:43 UTC |
Vanderhaegen FredericEVP, Europe
|
Tax withholdingCommon Stock | 398 | $28.69 | $11,418.62 |
DisclosureSEC source: 0001722482-21-000049 · wf-form4_161412017682811.xml · nonDerivative · entry 1 Vanderhaegen Frederic · CIK 0001776162 · EVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,388 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. F2 · balance_after: Includes 1,372 shares acquired under the Avantor Employee Stock Purchase Plan. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:42 UTC |
Stubblefield MichaelDirector · President and CEO
|
Tax withholdingCommon Stock | 10,141 | $28.69 | $290,945.29 |
DisclosureSEC source: 0001722482-21-000048 · wf-form4_161412011548370.xml · nonDerivative · entry 1 Stubblefield Michael · CIK 0001776153 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,437,122 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:39 UTC |
Ohri DevashishEVP, IMEA
|
Tax withholdingCommon Stock | 1,210 | $28.69 | $34,714.90 |
DisclosureSEC source: 0001722482-21-000046 · wf-form4_161411997413028.xml · nonDerivative · entry 1 Ohri Devashish · CIK 0001776125 · EVP, IMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,461 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 23:23 UTC |
Wondrasch MichaelEVP & CIO
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $23.20 | $0.00 |
DisclosureSEC source: 0001722482-21-000038 · wf-form4_161282658961712.xml · derivative · entry 4 Wondrasch Michael · CIK 0001776065 · EVP & CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,415 Underlying: Common Stock · 40,000 shares Expires 2028-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reflects an initial grant of 270,415 stock options in which 40% vested at the time of IPO and the remaining 60% that vests in four equal installments beginning on March 30, 2019. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 23:23 UTC |
Wondrasch MichaelEVP & CIO
|
SaleCommon Stock | 40,000 | $29.77 | $1,190,800.00 |
DisclosureSEC source: 0001722482-21-000038 · wf-form4_161282658961712.xml · nonDerivative · entry 3 Wondrasch Michael · CIK 0001776065 · EVP & CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,543 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $29.68 to $29.90, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 23:23 UTC |
Wondrasch MichaelEVP & CIO
|
Exercise / conversionCommon Stock | 40,000 | $23.20 | $928,000.00 |
DisclosureSEC source: 0001722482-21-000038 · wf-form4_161282658961712.xml · nonDerivative · entry 2 Wondrasch Michael · CIK 0001776065 · EVP & CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 23:23 UTC |
Wondrasch MichaelEVP & CIO
|
SaleCommon Stock | 9,468 | $29.77 | $281,862.36 |
DisclosureSEC source: 0001722482-21-000038 · wf-form4_161282658961712.xml · nonDerivative · entry 1 Wondrasch Michael · CIK 0001776065 · EVP & CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,543 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $29.68 to $29.90, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. F2 · balance_after: Includes 1,037 shares acquired under the Avantor Employee Stock Purchase Plan. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 22:05 UTC |
Murray Mark ChristopherEVP, Biomaterials & AT
|
Tax withholdingCommon Stock | 918 | $29.20 | $26,805.60 |
DisclosureSEC source: 0001722482-21-000029 · wf-form4_161074830047297.xml · nonDerivative · entry 1 Murray Mark Christopher · CIK 0001800013 · EVP, Biomaterials & AT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,458 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 17:43 UTC |
Bramwell JamesEVP, Strategic Partners
|
SaleCommon Stock | 2,505 | $30.00 | $75,150.00 |
DisclosureSEC source: 0001722482-21-000027 · wf-form4_161057781606784.xml · nonDerivative · entry 1 Bramwell James · CIK 0001776099 · EVP, Strategic Partners 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,430 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 1,167 shares acquired under the Avantor Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.